{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05289492",
      "orgStudyIdInfo": {
        "id": "TIG-007"
      },
      "organization": {
        "fullName": "iTeos Therapeutics",
        "class": "INDUSTRY"
      },
      "briefTitle": "Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma",
      "officialTitle": "Study of EOS884448 Alone, and in Combination with Iberdomide with or Without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma"
    },
    "statusModule": {
      "statusVerifiedDate": "2024-10",
      "overallStatus": "TERMINATED",
      "whyStopped": "Company operational decision. Decision to stop study is not due to safety or efficacy concerns",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2022-05-01",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2023-11-29",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2023-11-29",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2022-03-11",
      "studyFirstSubmitQcDate": "2022-03-18",
      "studyFirstPostDateStruct": {
        "date": "2022-03-21",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2024-10-23",
      "lastUpdatePostDateStruct": {
        "date": "2024-10-26",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "iTeos Therapeutics",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "Bristol-Myers Squibb",
          "class": "INDUSTRY"
        },
        {
          "name": "GlaxoSmithKline",
          "class": "INDUSTRY"
        },
        {
          "name": "iTeos Belgium SA",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM)."
    },
    "conditionsModule": {
      "conditions": [
        "Multiple Myeloma"
      ],
      "keywords": [
        "Multiple Myeloma",
        "EOS884448",
        "GSK4428859A",
        "TIGIT",
        "Anti-TIGIT",
        "iberdomide",
        "CELMoD",
        "CC-220",
        "EOS-448",
        "Belrestotug"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "SEQUENTIAL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 16,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "A: Participants will receive EOS884448",
          "type": "EXPERIMENTAL",
          "description": "EOS884448 will be administered",
          "interventionNames": [
            "Drug: EOS884448"
          ]
        },
        {
          "label": "B: Participants will receive EOS884448 and iberdomide",
          "type": "EXPERIMENTAL",
          "description": "EOS884448 and iberdomide will be administered",
          "interventionNames": [
            "Drug: EOS884448",
            "Drug: Iberdomide"
          ]
        },
        {
          "label": "C: Participants will receive EOS884448, iberdomide and dexamethasone",
          "type": "EXPERIMENTAL",
          "description": "EOS884448, iberdomide and dexamethasone will be administered",
          "interventionNames": [
            "Drug: EOS884448",
            "Drug: Iberdomide",
            "Drug: Dexamethasone"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "EOS884448",
          "description": "EOS884448 will be administered in arm A,B and C",
          "armGroupLabels": [
            "A: Participants will receive EOS884448",
            "B: Participants will receive EOS884448 and iberdomide",
            "C: Participants will receive EOS884448, iberdomide and dexamethasone"
          ],
          "otherNames": [
            "EOS-448, GSK4428859A, Belrestotug"
          ]
        },
        {
          "type": "DRUG",
          "name": "Iberdomide",
          "description": "Iberdomide will be administered in arm B and C",
          "armGroupLabels": [
            "B: Participants will receive EOS884448 and iberdomide",
            "C: Participants will receive EOS884448, iberdomide and dexamethasone"
          ],
          "otherNames": [
            "CC-220"
          ]
        },
        {
          "type": "DRUG",
          "name": "Dexamethasone",
          "description": "Dexamethasone will be administered in arm C",
          "armGroupLabels": [
            "C: Participants will receive EOS884448, iberdomide and dexamethasone"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of participants with any adverse events (AEs) and serious adverse events (SAEs)",
          "timeFrame": "From first study treatment administration up to 120 days after the last dose"
        },
        {
          "measure": "Number of participants with dose limiting toxicity (DLT)",
          "timeFrame": "From first study treatment administration up to 120 days after the last dose"
        },
        {
          "measure": "Recommended Phase 2 dose (RP2D) of EOS884448 alone or in combinations with iberdomide with or without dexamethasone in participants with relapse/refractory multiple myeloma",
          "timeFrame": "up to 2 years"
        },
        {
          "measure": "Number of participants with overall response (partial or better) as determined by IMWG criteria",
          "timeFrame": "up to 2 years"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Progression-free-survival (PFS)",
          "timeFrame": "Until disease progression or death - Approximately 24 months"
        },
        {
          "measure": "Duration of Response (DOR)",
          "timeFrame": "Until disease progression or death - Approximately 24 months"
        },
        {
          "measure": "Time to Response (TTR)",
          "timeFrame": "Approximately 48 weeks"
        },
        {
          "measure": "Maximum concentration (Cmax) of EOS884448 at each dose level",
          "timeFrame": "Approximately 48 weeks"
        },
        {
          "measure": "Percentage of participants with anti-drug antibodies to EOS884448",
          "timeFrame": "Approximately 48 weeks"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* All participants must have a documented diagnosis of relapse/refractory Multiple Myeloma and have measurable disease as defined per IMWG criteria.\n* All participants must have received at least 3 prior lines of MM therapy with IMiD, PI and Anti-CD-38, and progressed on their last therapy (prior BCMA targeted therapy allowed).\n* All participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1or 2.\n* All participants must have adequate organ function.\n* Females of childbearing potential (FCBP) or male participant must agree to follow contraception requirements.\n\nExclusion Criteria:\n\n* All participants with non-secretory MM\n* All participants with known auto-immune disease\n* All participants with history of life-threatening toxicity related to prior immune therapy.\n* All participants with active graft versus host disease after allogeneic stem cell transplantation.\n* All participants with active, unstable cardiovascular function.\n* All participants with active infection requiring systemic therapy.\n* All participants with hypersensitivity to any of the treatments.\n* All participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Iteos Clinical Trials",
          "affiliation": "iTeos Belgium SA",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "Banner MD Anderson",
          "city": "Gilbert",
          "state": "Arizona",
          "zip": "85234",
          "country": "United States",
          "geoPoint": {
            "lat": 33.35283,
            "lon": -111.78903
          }
        },
        {
          "facility": "Eastern Connecticut Hematology & Oncology",
          "city": "Norwich",
          "state": "Connecticut",
          "zip": "06360",
          "country": "United States",
          "geoPoint": {
            "lat": 41.52426,
            "lon": -72.07591
          }
        },
        {
          "facility": "Hackensack University Medical Center",
          "city": "Hackensack",
          "state": "New Jersey",
          "zip": "07601",
          "country": "United States",
          "geoPoint": {
            "lat": 40.88593,
            "lon": -74.04347
          }
        },
        {
          "facility": "Fred Hutchinson Cancer Center",
          "city": "Seattle",
          "state": "Washington",
          "zip": "98109",
          "country": "United States",
          "geoPoint": {
            "lat": 47.60621,
            "lon": -122.33207
          }
        },
        {
          "facility": "ZNA Cadix",
          "city": "Antwerp",
          "zip": "2020",
          "country": "Belgium",
          "geoPoint": {
            "lat": 51.22047,
            "lon": 4.40026
          }
        },
        {
          "facility": "Institut Jules Bordet",
          "city": "Brussels",
          "zip": "1070",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.85045,
            "lon": 4.34878
          }
        },
        {
          "facility": "Universitaire Ziekenhuizen KU Leuven",
          "city": "Leuven",
          "zip": "3000",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.87959,
            "lon": 4.70093
          }
        },
        {
          "facility": "CHU Amiens",
          "city": "Amiens",
          "zip": "80054",
          "country": "France",
          "geoPoint": {
            "lat": 49.9,
            "lon": 2.3
          }
        },
        {
          "facility": "Centre Hospitalier Universitaire de Nantes",
          "city": "Nantes",
          "zip": "44093",
          "country": "France",
          "geoPoint": {
            "lat": 47.21725,
            "lon": -1.55336
          }
        },
        {
          "facility": "APHP HÃ´pital Saint-Antoine",
          "city": "Paris",
          "zip": "75012",
          "country": "France",
          "geoPoint": {
            "lat": 48.85341,
            "lon": 2.3488
          }
        },
        {
          "facility": "CHU de Poitiers",
          "city": "Poitiers",
          "zip": "86021",
          "country": "France",
          "geoPoint": {
            "lat": 46.58261,
            "lon": 0.34348
          }
        },
        {
          "facility": "CHU Toulouse",
          "city": "Toulouse",
          "zip": "31059",
          "country": "France",
          "geoPoint": {
            "lat": 43.60426,
            "lon": 1.44367
          }
        },
        {
          "facility": "Hospital Fundacion Jimenez Diaz",
          "city": "Madrid",
          "zip": "28040",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-18"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D009101",
          "term": "Multiple Myeloma"
        }
      ],
      "ancestors": [
        {
          "id": "D054219",
          "term": "Neoplasms, Plasma Cell"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D020141",
          "term": "Hemostatic Disorders"
        },
        {
          "id": "D014652",
          "term": "Vascular Diseases"
        },
        {
          "id": "D002318",
          "term": "Cardiovascular Diseases"
        },
        {
          "id": "D010265",
          "term": "Paraproteinemias"
        },
        {
          "id": "D001796",
          "term": "Blood Protein Disorders"
        },
        {
          "id": "D006402",
          "term": "Hematologic Diseases"
        },
        {
          "id": "D006425",
          "term": "Hemic and Lymphatic Diseases"
        },
        {
          "id": "D006474",
          "term": "Hemorrhagic Disorders"
        },
        {
          "id": "D008232",
          "term": "Lymphoproliferative Disorders"
        },
        {
          "id": "D007160",
          "term": "Immunoproliferative Disorders"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000624220",
          "term": "iberdomide"
        },
        {
          "id": "D003907",
          "term": "Dexamethasone"
        }
      ],
      "ancestors": [
        {
          "id": "D011246",
          "term": "Pregnadienetriols"
        },
        {
          "id": "D011245",
          "term": "Pregnadienes"
        },
        {
          "id": "D011278",
          "term": "Pregnanes"
        },
        {
          "id": "D013256",
          "term": "Steroids"
        },
        {
          "id": "D000072473",
          "term": "Fused-Ring Compounds"
        },
        {
          "id": "D011083",
          "term": "Polycyclic Compounds"
        },
        {
          "id": "D013259",
          "term": "Steroids, Fluorinated"
        }
      ]
    }
  },
  "hasResults": false
}